T Cell Activation and Immune Cell Function in Melanoma Patients Treated With recMAGE-A3 + AS15 Immunological Adjuvant System

Trial Profile

T Cell Activation and Immune Cell Function in Melanoma Patients Treated With recMAGE-A3 + AS15 Immunological Adjuvant System

Completed
Phase of Trial: Phase 0

Latest Information Update: 06 Apr 2016

At a glance

  • Drugs Zastumotide (Primary) ; Zastumotide (Primary) ; AS15; AS15
  • Indications Malignant melanoma
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms Mel55
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Apr 2016 Last checked against ClinicalTrials.gov record (NCT01425749).
    • 06 Apr 2016 Last checked against ClinicalTrials.gov record (NCT01425749).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top